CAPOX (oxaliplatin/capecitabine)

DRUG5 trials

Sponsors

Zealand University Hospital, Sun Yat-sen University, RemeGen Co., Ltd., Kaohsiung Medical University Chung-Ho Memorial Hospital, Guangdong Provincial People's Hospital

Conditions

CapecitabineChemotherapy EffectColorectal CancerColorectal NeoplasmGC/GEJCGastric CarcinomaIntestinal DiseaseIntestinal Neoplasms

Phase 1

Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma

Not yet recruitingNCT07680569

Kaohsiung Medical University Chung-Ho Memorial HospitalGC/GEJC

Start: 2026-06-01End: 2027-12-01Target: 40Updated: 2026-07-02

Phase 2

NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer

Zealand University HospitalChemotherapy Effect, Colorectal Cancer, Colorectal Neoplasm +4

Start: 2017-03-01End: 2024-12-31Target: 124Updated: 2017-09-28

A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Not yet recruitingNCT06919510

Sun Yat-sen UniversityRectal Adenocarcinoma

Start: 2025-04-01End: 2028-12-01Target: 90Updated: 2025-04-09

Phase 3

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

RecruitingNCT07315750

RemeGen Co., Ltd.Gastric Carcinoma

Start: 2026-01-01End: 2030-12-31Target: 555Updated: 2026-01-21

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

Not yet recruitingNCT07686796

Guangdong Provincial People's HospitalCapecitabine, Local Advanced Rectal Cancer, Oxaliplatin +4

Start: 2027-01-01End: 2035-01-01Target: 148Updated: 2026-07-07

Related Papers

Efficacy and safety of disitamab vedotin (DV) combined with trastuzumab, and tislelizumab versus chemotherapy (CAPOX) combined with trastuzumab ± pembrolizumab for patients with first-line HER2-high advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA): A randomized controlled phase 3 trial.

Journal of Clinical Oncology2026-05-28